Cancer Drug Targets and Brain 'Brakes' Offer New Hope for Chronic Nerve Pain
Two recent studies identify distinct biological mechanisms for chronic nerve pain, offering potential new treatment avenues. Researchers at MD Anderson found that the cancer-linked protein BRAF travels to the spinal cord after nerve injury, activating NMDA receptors to sustain pain; existing cancer drugs like vemurafenib reduced pain sensitivity in preclinical models. Simultaneously, Washington University researchers identified a 'brake' in the brain's locus coeruleus, where mu opioid receptors normally suppress pain signals. Disrupting this brake increases pain sensitivity, suggesting that targeting this specific brain region could provide relief without the widespread side effects of traditional opioids. Both studies remain preclinical, highlighting the need for human trials to determine safety and efficacy.